SMR3A

Across TCGA pan-cancer cohorts, SMR3A mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of SMR3A’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where SMR3A mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types SMR3A is over-expressed in tumor, although a few such as HNSC show the opposite, repressed pattern.

HNSC, LSCC, and PDAC are the cancer types where SMR3A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SMR3A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	All	−0.303	.042	2	view →
LSCC	Male	All	+0.251	.011	2	view →
PDAC	Male	All	+0.484	.036	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

SMR3A–HNSC

Open the HNSC breakdown →